Category Archives: Stem Cell Clinic

Breakthrough motor neurone disease study finds way to reverse damage – The National

SCIENTISTS in Scotland have made a very exciting breakthrough in the race to find a cure for motor neurone disease.

Researchers at the University of Edinburgh identified a key cause of the illness which could be combatted by repurposing drugs approved for other diseases.

There is no known cure for MND, a condition which stops signals from the brain reaching the muscles, damaging them over time. More than 1500 people in the UK are diagnosed with the disease every year.

The new study was carried out at the Euan MacDonald Centre for MND Research.

The team there discovered that the damage to nerve cells caused by MND could be repaired by improving the energy levels in mitochondria the power supply to the motor neurons.

They found that in human stem cell models of MND, the axon the long part of the motor neuron cell that connects to the muscle was shorter than in healthy cells. The movement of the mitochondria, which travel up and down the axons, were also impaired.

The scientists showed that this was caused by a defective energy supply from the mitochondria and that by boosting the mitochondria, the axon reverted back to normal.

Dr Arpan Mehta, who led the study at Euan MacDonald Centre for MND research said: "The importance of the axon in motor nerve cells cannot be understated.

"Our data provides hope that by restoring the cell's energy source we can protect the axons and their connection to muscle from degeneration.

"Work is already under way to identify existing licensed drugs that can boost the mitochondria and repair the motor neurons. This will then pave the way to test them in clinical trials."

Dr Arpan Mehta led the research at Edinburgh University's Euan MacDonald Centre

The study was welcomed by by charities including the foundation set up by Scots rugby legend Doddie Weir.

My Name'5 Doddie foundation described it as "a very exciting breakthrough".

The researchers used stem cells taken from people with the C9orf72 gene mutation that causes both MND and frontotemporal dementia.

They used the stem cells to generate motor neuron cells in the lab.

The study also used human post-mortem spinal cord tissue from people with MND.

Although the research focused on the people with the commonest genetic cause of MND, the researchers said they were hopeful the results would also apply to other forms of the disease.

The results of the study are now being used to look for existing drugs that boost mitochondrial function.

Craig Stockton, the chief executive of MND Scotland, also welcomed the news.

"We look forward to seeing if these positive results can be replicated for patients," he said.

"Once researchers have identified a drug they believe could have the desired effect, this treatment could then be fast-tracked for human trials using the pioneering MND-SMART clinical trial platform into which MND Scotland has invested 1.5m.

"Researchers, clinicians, charities and supporters are all working hard to take us closer to finding a cure and by joining together we'll get to that day even sooner."

The study was funded by the Medical Research Council, Motor Neurone Disease Association, Euan MacDonald Centre for MND Research, My Name'5 Doddie Foundation, UK Dementia Research Institute and Anne Rowling Regenerative Neurology Clinic.

Continued here:
Breakthrough motor neurone disease study finds way to reverse damage - The National

Orchard Therapeutics Announces 2021 Corporate Priorities Supporting the Build-out of its Commercial Business in Hematopoietic Stem Cell (HSC) Gene…

January 11, 2021 07:00 ET | Source: Orchard Therapeutics (Europe) Limited

Preparations on Track for First Half 2021 Commercial Launch of Libmeldy (OTL-200), the First Approved Product for Metachromatic Leukodystrophy (MLD) in the EU

Filing Strategy for OTL-200 Biologics License Application (BLA) in MLD in the U.S. to be Communicated by Mid-2021 Following Additional Regulatory Interactions

Marketing Authorization Application (MAA) Filing for OTL-103 in Wiskott-Aldrich Syndrome (WAS) on Track for Year End 2021 in the EU; Followed by BLA Filing in 2022 in the U.S.

New Clinical Data for OTL-203 (for MPS-I) and OTL-201 (for MPS-IIIA) Accepted for Oral Presentation at February 2021 WORLD Symposium; Preclinical Data from Research Programs in Larger Indications Expected in 2021

$192M in Cash and Investments to Support Strategic Execution into the First Half of 2022

BOSTONandLONDON, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined the companys 2021 strategic priorities in advance of its attendance at the virtual 39thAnnual J.P. Morgan Healthcare Conference. These priorities support the companys plan of building a successful commercial business in HSC gene therapy and advancing its portfolio of investigational medicines for high-value, high-need indications.

In a year that challenged how we live and work, Im extremely proud of Orchards achievements in 2020, said Bobby Gaspar, M.D., Ph.D., chief executive officer, Orchard Therapeutics. Our accomplishments were a direct result of the drive and innovation that fuels our commitment to bring our potentially life-saving HSC therapies to patients, including Libmeldy, which is the first product approved for the treatment of eligible patients with early-onset MLD in the EU. With the HSC approach to gene therapy as our scientific foundation, we are focused on the capabilities that can deliver our therapies on a global commercial scale and support our ability to also treat larger indications over time. It has been a privilege to be a pioneer in changing the way medicine is practiced in these conditions, and we look forward to another year of continued execution and scientific progress.

2021 Corporate Priorities Orchard has outlined the following key corporate objectives and expected milestones for 2021:

In preparation for a European launch, Orchard has put in place the commercial infrastructure to support Libmeldy as well as future product launches. The company is qualifying five treatment centers in the UK, Germany, Italy, France and the Netherlands with specialized expertise in transplant and disease area knowledge. In addition, the company expects to leverage cross-border and treatment abroad reimbursement pathways in both Europe and markets such as the Middle East and Turkey. Activities are also underway to drive timely MLD patient identification and access, including disease awareness, genetic testing and newborn screening studies, which have started or are on track to initiate in five countries in 2021.

The company also provided an update concerning the impact of the COVID-19 pandemic on certain development activities. These include restrictions to laboratory access at Orchard and third-party service providers, which is impacting the timeline to develop a specific functional potency assay for OTL-103 in WAS, as requested by the FDA. As a result, the company now expects to file a BLA for OTL-103 in the U.S. in 2022. Orchard is utilizing the benefits provided under OTL-103s RMAT designation and plans to continue interacting with the FDA in 2021 to confirm the data package for the BLA filing. In addition, with several of the follow-up visits associated with the companys active clinical trials impacted by COVID-19 travel restrictions and other trial site limitations, Orchard is using alternative data collection approaches to capture the necessary data to support future regulatory filings.

Frank Thomas, president and chief operating officer continued, Starting 2021 with a clear set of strategic priorities is crucial to our ability to effectively manage the business while fueling Orchards continued growth. Our launch preparations for Libmeldy not only mark our evolution towards a fully integrated company but establish a common manufacturing, commercial and operational infrastructure to support multiple future potential products. This work is complemented by our exciting proof-of-concept and research pipeline that we look forward to advancing internally or in partnership.

Key 2020 Achievements Orchards key 2020 achievements are highlighted below.

Cash Guidance The company ended 2020 with approximately $192 million of cash and investments. The company expects that its cash, cash equivalents and marketable securities as of December 31, 2020 will enable the funding of its currently anticipated operating expenses and capital expenditure requirements into the first half of 2022. This excludes the $50 million expected to be available under the companys credit facility and any non-dilutive capital received from potential future partnerships or priority review vouchers.

About Libmeldy / OTL-200

Libmeldy (autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase-A (ARSA) gene), also known as OTL-200, has been approved by the European Commission for the treatment of MLD in eligible early-onset patients characterized by biallelic mutations in the ARSA gene leading to a reduction of the ARSA enzymatic activity in children with i) late infantile or early juvenile forms, without clinical manifestations of the disease, or ii) the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline. Libmeldy is the first therapy approved for eligible patients with early-onset MLD.

The most common adverse reaction attributed to treatment with Libmeldy was the occurrence of anti-ARSA antibodies. In addition to the risks associated with the gene therapy, treatment with Libmeldy is preceded by other medical interventions, namely bone marrow harvest or peripheral blood mobilization and apheresis, followed by myeloablative conditioning, which carry their own risks. During the clinical studies, the safety profiles of these interventions were consistent with their known safety and tolerability.

For more information about Libmeldy, please see the Summary of Product Characteristics (SmPC) available on the EMA website.

Libmeldy is not approved outside of the European Union, UK, Iceland, Liechtenstein and Norway. OTL-200 is an investigational therapy in the US.

Libmeldy was developed in partnership with the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy.

About Orchard

Orchard Therapeuticsis a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Ourex vivoautologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and theSan Raffaele Telethon Institute for Gene Therapy inMilan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters inLondonandU.S.headquarters inBoston. For more information, please, and follow us on TwitterandLinkedIn.

Availability of Other Information About Orchard

Investors and others should note that Orchard communicates with its investors and the public using the company website (, the investor relations website (, and on social media (TwitterandLinkedIn), including but not limited to investor presentations and investor fact sheets,U.S. Securities and Exchange Commissionfilings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-Looking Statements

This press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, including its plans and expectations for the commercialization of Libmeldy, the therapeutic potential of Libmeldy (OTL-200) and Orchards product candidates, including the product candidates referred to in this release, Orchards expectations regarding its ongoing preclinical and clinical trials, including the timing of enrollment for clinical trials and release of additional preclinical and clinical data, the likelihood that data from clinical trials will be positive and support further clinical development and regulatory approval of Orchard's product candidates, and Orchards financial condition and cash runway into the first half of 2022. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the risk that prior results, such as signals of safety, activity or durability of effect, observed from clinical trials of Libmeldy will not continue or be repeated in our ongoing or planned clinical trials of Libmeldy, will be insufficient to support regulatory submissions or marketing approval in the US or to maintain marketing approval in the EU, or that long-term adverse safety findings may be discovered; the risk that any one or more of Orchards product candidates, including the product candidates referred to in this release, will not be approved, successfully developed or commercialized; the risk of cessation or delay of any of Orchards ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates; the delay of any of Orchards regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates or the receipt of restricted marketing approvals; the inability or risk of delays in Orchards ability to commercialize its product candidates, if approved, or Libmeldy, including the risk that Orchard may not secure adequate pricing or reimbursement to support continued development or commercialization of Libmeldy; the risk that the market opportunity for Libmeldy, or any of Orchards product candidates, may be lower than estimated; and the severity of the impact of the COVID-19 pandemic on Orchards business, including on clinical development, its supply chain and commercial programs. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards quarterly report on Form 10-Q for the quarter endedSeptember 30, 2020, as filed with theU.S. Securities and Exchange Commission(SEC), as well as subsequent filings and reports filed with theSEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.


Investors Renee Leck Director, Investor Relations +1 862-242-0764

Media Christine Harrison Vice President, Corporate Affairs +1 202-415-0137

Read this article:
Orchard Therapeutics Announces 2021 Corporate Priorities Supporting the Build-out of its Commercial Business in Hematopoietic Stem Cell (HSC) Gene...

Cancer Stem Cell Therapy Market : Information, Figures And Analytical Insights 2020-2026 – LionLowdown

Cancer Stem Cell Therapy Industry offers a detailed snapshot of projected Sales and Trends for 2020-2026:

Regal Intelligences most recent report on Cancer Stem Cell Therapy global markets analyzes the impact of the novel coronavirus (COVID-19) on the industry. The report includes the global industry outlook in the light of the current market situation, trends, key industry players, and how these factors are expected to boost the Cancer Stem Cell Therapy market over the projection horizon.

The regal intelligence research study examines the dynamic factors that will soon affect the Cancer Stem Cell Therapy market. In addition, market analysis based on key elements such as regional market assessment and sector analysis is assessed in this report so that readers can make informed business decisions with accuracy.

Prominent players covered in this report are AVIVA BioSciences AdnaGen Advanced Cell Diagnostics Silicon Biosystems

Download Sample Report of Cancer Stem Cell Therapy Market @

The report studies key players in the industry and analyses their competitive landscape. These key players determine the growth of the market in various segments and regions. The report evaluates critical points that reflect solutions and services for the market. Furthermore, the report studies verticals of the market, upstream channels of raw material supply, the downstream channel of demand distribution, and the production value of leading players in the industry subject to market growth in the near future.

Impact of COVID-19:

Cancer Stem Cell Therapy Market Major End-users: Hospital Clinic Medical Research Institution Others

Cancer Stem Cell Therapy Market Segment by Product Types: Autologous Stem Cell Transplants Allogeneic Stem Cell Transplants Syngeneic Stem Cell Transplants Others

The period considered to estimate the market size of the Cancer Stem Cell Therapy is as follows:

Historic Year: 2015-2020|Base Year: 2020|Estimated Year: 2021|Forecast Year 2020 to 2026

Market Segmentation:

The report looks at various segments of the global Cancer Stem Cell Therapy market based on end-user type, product type, the application along with regional analysis. The researchers are carefully looking at these market segments to provide ingenious insights across different segments of the market. These segments are considered at critical touchpoints such as market share, market revenue, region-wise growth, cost of production, revenue and cost analysis, and many factors are taken into account in segment analysis. These segmentation analyses assist readers in understanding the market growth over the forecast period, by segment and in making informed decisions accordingly.

Get Special Discount on New Year [emailprotected]

Primary Objectives of Cancer Stem Cell Therapy market Report:

It is summarized that the report assesses the geographic segments of the market, the analyses, the competitive landscape of the major players in the industry, various analyses of costs and revenues, growth factors, trends, as well as future projections. The report also comprises the studies on BCG matrix analysis, SWOT, and pestle, along with five forces analysis to evaluate market potential and growth factors. Meanwhile, this report also assists the investors to obtain information on the feasibility of investments in various industrial avenues and the factors of return on investments analyzed in-depth.

There are more than just insights and perspectives from the industry; wed be happy to hear from you at [emailprotected]

Read more here:
Cancer Stem Cell Therapy Market : Information, Figures And Analytical Insights 2020-2026 - LionLowdown

Paint it all Pink winner charity donation helps Elizabeth Wende Breast Care Fund –

Julie Sherwood |MPNnow

Theyve been best friends for over 60 years: Cathie Donner, Lynda Lochner and Sue Simpatico. All 1969 graduates of Nazareth Academy in Rochester, the three havent let the demands of career and family stand in the way of making time for one another. That goes for a tradition started years ago of getting together on the day of their scheduled mammograms at Elizabeth Wende Breast Care.

Donner said they go out for coffee that day and its a good excuse to catch up while they stay on track with their annual breast exams.

It all changed in 2014, when Simpatico was diagnosed with lymphoma and breast cancer. Early diagnosis led to further tests, decisions about options and then treatment that included stem cell replacement, chemotherapy and a mastectomy an ordeal no one ever wants to go through.

Simpatico recovered from cancer, and her experience inspired Donner to donate the charity portion of her winnings in a national contest to the Elizabeth Wende Breast Care Fund. Created at Rochester Area Community Foundation by physicians of Elizabeth Wende Breast Care, LLC in 2008, the fund supports care, diagnostic education and research regarding breast health and cancer.

I am very grateful and thankful, said Donner, grand prize winner of Gannett Media Groups Paint it all Pink contest. Donner received a check for $5,000 and on her behalf, Gannett made a donation of $5,000 to her chosen breast cancer charity, Elizabeth Wende Breast Care Fund.

Contestants took an online quiz about breast cancer awareness. Donner, a Chili resident, said she took the quiz awhile back and didnt give it much thought afterwards. Then she learned she won, her entry having been the first chosen in the drawing.

A lot of patients have said, I am so thankful, and they wanted to do something, said Dr. Stamatia Destounis, a provider at Elizabeth Wende Breast Care in Rochester. That is what inspired the physicians of Elizabeth Wende Breast Care in 2008 to create the Elizabeth Wende Breast Care Fund at the Rochester Area Community Foundation. Dr. Destounis said that by setting up the fund through the foundation, the monies could support area organizations that promote research and education centered on breast cancer and breast health.

The Rochester Area Community Foundation, in partnership with philanthropists and community partners, works to improve the quality of life in the eight-county Rochester region through leadership and strategic grant-making.

All the monies stay in the community, said Destounis, who completed her radiology residency at the University of Rochester School of Medicine & Dentistry in 1993. She joined the Elizabeth Wende Breast Clinic and trained with its founder, Dr. Wende Logan Young, completing a breast imaging fellowship of one year and joining Elizabeth Wende Breast Clinic as an attending radiologist In July 1994.

Destounis said organizations that benefit from the fund include Breast Cancer Coalition of Rochester, the American Cancer Society, UR Medicine Wilmot Cancer Institute's Pluta Cancer Center and Embrace Your Sisters, which provides emergency breast cancer support, among others.

Elizabeth Wende Breast Care began in 1975 when Dr. Wende Logan Young opened the first dedicated breast clinic in the United States on Mt. Hope Avenue in Rochester. One of the largest freestanding breast imaging centers in the nation, it is the largest single-site breast imaging center in New York. Elizabeth Wende Breast Care states its mission has remained the same throughout the years and advances in breast imaging technology, to provide each of our patients with state-of-the art breast imaging, along with compassionate, personalized care.

Five runners up in the Paint it all Pink contest each received $500. One of the runners up is Katie Barnum of Canandaigua. Others are Geri Spera of Pueblo, Colorado; Melissa Dean of Spencer, Indiana; Judy Brazeal of Fayette, Alabama, and Kristina Schlueter of Delray Beach, Florida.

More here:
Paint it all Pink winner charity donation helps Elizabeth Wende Breast Care Fund -

Center for Regenerative Medicine – Mayo Clinic

Clinical Trials

Mayo Clinic offers a variety of clinical trials that are open for enrollment to participants who want to volunteer for research studies exploring regenerative medicine therapy.

Part of Mayo Clinic's commitment to its patients involves conducting medical research that can help people live longer, healthier lives. Clinical trials are research studies that involve volunteer participants. These studies help physician-scientists better understand, diagnose, treat, and prevent diseases and conditions.

Mayo Clinic's clinical trials related to regenerative medicine include studies on amytrophic lateral sclerosis (ALS), chronic obstructive pulmonary disease (COPD), congenital heart disease, diabetic kidney disease, Parkinson's disease, osteoarthritis and many more. Mayo Clinic also has thousands of other active clinical trials and research studies, and it coordinates national and international clinical trials with other medical institutions from around the world.

The Regenerative Medicine Consult Service, Mayo Clinic's front door to regenerative therapies and research, provides information and referrals to patients.

Phone: 844-276-2003 (toll-free)

Mayo Clinic has many active clinical trials related to transplantation, which is one component of regenerative medicine.


Center for Regenerative Medicine - Mayo Clinic

Cancer Stem Cell Therapy Market Revenue, Global Forecast, Cost, Key Participants and Emerging Trends and Key Players-AVIVA BioSciences , AdnaGen – The…

Summary of the Cancer Stem Cell Therapy Market Report

Rise in R&D activities across the globe, increase in demand and growth across several application areas are some of the factors boosting the growth of the market.

Key Companies

AVIVA BioSciences AdnaGen Advanced Cell Diagnostics Silicon Biosystems

Cancer Stem Cell Therapy Market by Type

Autologous Stem Cell Transplants Allogeneic Stem Cell Transplants Syngeneic Stem Cell Transplants Others

Cancer Stem Cell Therapy Market by Application

Hospital Clinic Medical Research Institution

The major regional market covered under the scope of the study are APAC, North America, Europe, South & Central America, Africa and the Middle East. Singapore, Russia, Mexico, South America, Canada, France, the U.S., Germany, Africa, Italy, the United Kingdom, India, China, the Middle East, Central America, Japan, South America, Taiwan, and South Korea among others.

To know more about the report, visit @

Cancer Stem Cell Therapy Market Overview, Key Trends Market Dynamics

Growth across various application areas and major geographies, growing R&D activities and rising demand are some of the key factors currently driving this market. The market would witness significant growth throughout the forecast period. Other factors are increasing the rate of adoption and improving the product that drives the demand at a fast pace. At present, i.e. 2020, the effect of COVID -19 can be seen; however, the market will soon recover in the coming years probably by 2021.

Regional Coverage of Global Cancer Stem Cell Therapy Market

Mexico, Canada, and the United States are the major countries covered under North America Italy, UK, Germany, Italy, UK, France, UK, Russia are covered under Europe Taiwan, India, China, South Korea, Singapore, Japan, and Others are covered under Asia Pacific Rest of the World (RoW) covers Africa, South America & Central America and the Middle East COVID -19 Impact Analysis

The report also offers a detailed insight of COVID -19 impact analysis:

Before COVID -19 Present Scenario Post recovery of COVID -19

Inquire Before Purchasing the report, visit @

Table of Content

Customization can be availed on Request:

Chapter 1: Introduction and Scope Chapter 2: Key Company Profiles Chapter 3: Remarks, Share and Forecast across type, application and geography Chapter 4: Market Remarks of Asia Pacific region Chapter 5: Market Remarks of Europe region Chapter 6: Market Remarks of Asia Pacific region Chapter 7: Market Remarks of North America region Chapter 8: Market Remarks of Middle East and Africa region Chapter 9: Key Important features of the market Chapter 10: Key trends of the market and the market Opportunities Chapter 11: Strategies to be adopted by the key players


Key Pointers of the Report

For each and every segment and its sub-segment, market share and growth rate are given Estimation and forecast provided from 2020 to 2027 Data triangulation method has been followed to conclude the market The study also includes the strategies to be followed by the major players COVID -19 impact analysis was also covered under the framework of impact analysis

Supplementary Pointers of the Report:

Stated below are some of the added key points of the report:

SWOT Analysis Porters Five Analysis Value Chain Analysis Market Attractiveness Analysis PEST Analysis

To Inquire about the Discount available with the report, visit @

Note: Year End Discount If you purchase the report this year Flat 15% instant discount 20% discount on 2nd report 1 Year consultation and 10 % free customization

Kindly contact us and our expert will get back to you within 30 minutes: Decisive Markets Insights Sunil Kumar Sales Head Email US +18317045538 UK +44125663604

Follow this link:
Cancer Stem Cell Therapy Market Revenue, Global Forecast, Cost, Key Participants and Emerging Trends and Key Players-AVIVA BioSciences , AdnaGen - The...

Cancer Stem Cell Therapy Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 – Cheshire Media

DATAINTELO has published a research report on the Cancer Stem Cell Therapy market. The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the report. It provides an in-depth analysis of the market segments which include products, applications, and end-user applications.

This report also includes a complete analysis of industry players that cover their latest developments, product portfolio, pricing, mergers, acquisitions, and collaborations. Moreover, it provides crucial strategies that are helping them to expand their market share. The Global Cancer Stem Cell Therapy Market research report is prepared by implying robust research methodology and including Porters Five Forces analysis to provide the complex matrix of the market.

Get Free Sample Report + All Related Graphs & Charts:

Key Highlights of the Report

Complete Purchase of Latest Version Global Cancer Stem Cell Therapy Market Study with COVID-19 Impact Analysis:

Market Segmentation Covered in the report.

By Type

Autologous Stem Cell Transplants Allogeneic Stem Cell Transplants Syngeneic Stem Cell Transplants Other

The market research report is classified into the types of products and is analyzed in a detailed manner. Moreover, it includes potential future products that are expected to open new market avenues and can change the dynamics of the market. Each product type is analyzed on the basis of their developments, growth, and threats in the different regions.

By Application

Hospital Clinic Medical Research Institution Other

This report covers all the applications of the afore-mentioned products and also provides information on the potential applications in the foreseeable future. The dedicated research team has to look into all possible parameters and analyzed the applications that drive the growth of the market.

By Region

North America (U.S., Canada, Mexico)

Asia Pacific (India, China, Japan, South Korea, ASEAN, Rest of Asia Pacific)

Europe (Italy, Germany, France, Spain, Central & Eastern Europe, Rest of Europe)

Middle East & Africa (GCC, Turkey, Rest of the Middle East & Africa)

South America (Brazil, Argentina, Rest of South America)

One country of interest can be added with no additional cost on the report. Moreover, if more than one needs to be added, the regional segment quote may vary. In this report, the questions such as which country/region is expected to witness a steep rise in CAGR & year-on-year (Y-o-Y) are also covered.

Ask for the discount @

Competitive Landscape

AVIVA BioSciences AdnaGen Advanced Cell Diagnostics Silicon Biosystems

Note: Additional companies can be profiled in the report.

Frequently asked questions (FAQs) about the report

1) Does the report cover COVID-19 impact and future market projections?

Yes. The market research report covers the detailed analysis of COVID-19 impact on the market. Our research team has been monitoring the market closely while it has been conducting interviews with the industry experts to get better insights on the present and future implications of the COVID-19 virus on the market.

The market report provides vital information on the strategies deployed by industry players during the COVID-19 crisis to maintain their position in the market. Along with this, it also shares crucial data on product developments due to the inevitable pandemic across the globe.

2) Can the report be customized according to the requirements?

Yes. The Cancer Stem Cell Therapy market report can be customized according to your needs. For instance, the company can be profiled you ask for while specific region/country analysis can be focused that meets your interests. You can talk to our research analyst about your exact requirements and DATAINTELO will accordingly tailor the required report.

3) Can we narrow the available business segments?

Yes, the market report can be further segmented on the basis of data availability and feasibility. We can provide a further breakdown in product types and applications (if applicable) by size, volume, or revenue. In the market segmentation part, the latest product developments and customer behavior insights are also included to give an in-depth analysis of the market.

Get on the call with our research analyst if you have any particular doubts before buying the report @

About US:

DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry.

Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473



More here:
Cancer Stem Cell Therapy Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - Cheshire Media

Short Redhead Reel Reviews for the week of Dec. 4 – ECM Publishers

Rating system: (4=Don't miss, 3=Good, 2=Worth a look, 1=Forget it)

For more reviews, click here.

76 Days (NR) (4) [Subtitled] [Opens Dec. 4 in Virtual Cinema sponsored by MSP Film Society (for more information, log on to and available on various VOD platforms.] A captivating, gut-wrenching, heartbreaking, informative, critically acclaimed, candid, moving, 93-minute documentary that follows the dedicated, caring, hazmat-suit-wearing medical staff at four Chinese hospitals, including the Wuhan Red Cross Hospital, during the 76-day lockdown between Jan. 23 and April 4 in Wuhan, China, in 2020 and their diligent attempts to treat and save an eclectic group of patients (such as a dementia-afflicted grandfather and a couple waiting in quarantine waiting to hold their newborn girl nicknamed little penguin) struggling with COVID-19 during the global pandemic.

Ending Disease (NR) (4) [Available Dec. 4 on various VOD platforms.] Joe Gantzs engaging, powerful, educational, inspirational, insightful, moving, 185-minute, four-part documentary that examines the passage of Proposition 71 in 2004 in California in which citizens agreed to fund $3 billion for stem cell and regenerative therapy research and follows ten FDA-approved clinical trials and progress of patients, including 19-year-old basketball player Ryan Custer who is a quadriplegic after a devastating spinal cord injury, Steve Sharples who is dealing with brain cancer, Rosie who is going blind from retinitis pigmentosa, gay man Andrew Caldwell coping with HIV/AIDS, anxiety-prone Korean Aaron who contracted HIV from a blood transfusion, young girl Ava who had a bone marrow transplant for an immune deficiency disorder called bubble baby disease, mother Cheryl who suffers from aggressive lymphoma, and Lucas Linder who had a spinal cord injury, participating in groundbreaking, controversial, and promising stem cell, CAR T-cell, and antibody therapies to hopefully cure or improve their condition and consists of commentary by numerous medical personnel involved in the trials, including Dr. Benham Badie, California institute of regenerative medicine (CIRM) first director Robert Klein, Dr. Henry Klassen at USC in Irvine, Dr. Amrita Krishnan at City of Hope, Dr. Nitya Nathwani at City of Hope, City of Hope trial coordinator Teresa Kim, Dr. John Zaia at City of Hope, Dr. Christopher Dvorak at University of San Francisco, Dr. Shekar Kurpad at Froedstet Hospital in Milwaukee, Paula Cannon PhD at USC, Dr. Richard Fessler at Rush Medical Center in Chicago, clinical research coordinator at USC in Irvine, Dr. Jay Lalezari at Quest Clinic in San Francisco, Dr. Jeff Grijalva, Dr. Stephen Forman at City of Hope, Dr. Judith Shizuru at Stanford, stem cell research director Dr. Irv Weissman at Stanford, Dr. Mike McCune at the Bill and Melinda Gates Foundation, and 31-year cancer survivor Ellen who was the first person to receive stem cell therapy.

The Life Ahead (PG-13) (3.5) [Thematic content, drug material involving minors, some sexual material, and language.] [Netflix only] A somber, moving, well-acted, realistic, raw, down-to-earth, 94-minute remake of Moshe Mizrahis 1977 film and based on Romain Garys novel The Life Before Us in which a streetwise, angry, lonely, orphaned, 12-year-old, Senegalese Muslim immigrant (Ibrahima Gueye), who resorts to selling cocaine for a greedy drug dealer (Massimiliano Rossi), reluctantly agrees to live with an elderly, traumatized, PTSD-afflicted Auschwitz survivor and former prostitute (Sophia Loren) who cares for children (Babak Karimi, et al.) of prostitutes (Abril Zamora, et al.) in a small coastal town in Italy and finds a friendship they both desperately need.

Red Riding: 1974, Part 1 (NR) (2) [DVD and VOD only] A heavy Yorkshire accent and a convoluted plot hinder this dark, well-acted, slow-moving, factually inspired film noir, which is directed by Julian Jarrold and adapted from David Peace's bestselling crime novels and based on the Yorkshire ripper case, about an ambitious, idealistic crime journalist (Andrew Garfield) who suffers beating and after beating as he investigates the rape and brutal murder of a young girl in 1974 and stumbles on a corrupt police force (David Morrissey, John Henshaw, Warren Clarke, et al.) in Yorkshire and a greedy land developer (Sean Bean) while falling for the mother (Rebecca Hall) of one victim.

Red Riding: 1980, Part 2 (NR) (2.5) [DVD and VOD only] When a Manchester detective (Paddy Considine), who is cheating on his wife (Lesley Sharp) with a colleague (Maxine Peake), is assigned to head up a team (John Henshaw, Sean Harris, et al.) to investigate the alleged thirteenth victim of the Yorkshire killer in 1980 in this superbly acted, muddled, bleak, factually inspired film noir, which is directed by James Marsh and adapted from David Peace's bestselling crime novels and based on the Yorkshire ripper case, he uncovers a layer of corruption in the police force (David Morrissey, James Fox, Warren Clarke, et al.) and lie after lie in the case.

Red Riding: 1983, Part 3 (NR) (2.5) [DVD and VOD only] In this final trilogy installment, which is equally well acted but hard-to-follow, of the factually inspired, atmosphere-laden, slow-paced film noir, which was directed by Anand Tucker, a Yorkshire solicitor (Mark Addy) becomes convinced, and eventually convinces the shady police superintendent (David Morrissey), that the dimwitted prisoner (Daniel Mays) who they incarcerated six year earlier for the murder of a schoolgirl when he copped to the crime is actually innocent after another 10-year-old girl goes missing.

Sound of Metal (R) (3.5) [Language throughout and brief nude images.] [Available Dec. 6 available on Amazon Prime Video.] When a former heroin-addicted, heavy-metal drummer (Riz Ahmed) suddenly loses his hearing after nightly gigs and his girlfriend/musical partner (Olivia Cooke), whose widowed father (Mathieu Amalric) lives in Paris, becomes increasingly concerned in this touching, enlightening, realistic, thought-provoking, well-acted, 130-minute, 2019 film, he struggles to accept his situation, contemplates getting cochlear implants, and finally agrees to enter a deaf community after accepting help from a deaf veteran (Paul Ravi), who lost his hearing in Viet Nam, and an ASL teacher (Lauren Ridloff).

Wendy Schadewald is a Burnsville resident.

Read more:
Short Redhead Reel Reviews for the week of Dec. 4 - ECM Publishers

Human sperm stem cells grown in lab, an early step toward infertility treatment – Jill Lopez

Infertility affects one in seven men of reproductive age worldwide. One idea for treating male sterility is spermatogonial stem cell (SSC) therapy. In this approach, sperm stem cells in the testis are transferred to a test tube, cultured and nudged into becoming fully fledged sperm. However, a key bottleneck has been identifying just the right conditions to get human SSCs to grow in the lab. There have been many attempts, but in most reported cases it was not clear whether the cells being cultured were actually SSCs, and no previously published method is routinely used.

Researchers at University of California San Diego School of Medicine have now developed a reliable method for culturing cells with the characteristics of human SSCs. Their work is published in the July 13, 2020 issue ofProceedings of the National Academy of Sciences.

"We think our approach -- which is backed up by several techniques, including single-cell RNA-sequencing analysis -- is a significant step toward bringing SSC therapy into the clinic," said senior author Miles Wilkinson, PhD, Distinguished Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at UC San Diego School of Medicine.

SSCs are what make it possible for men to father children beyond the age of 65. These specialized cells continually self-renew, making more SSCs, and develop into sperm so prolifically that men (and some transgender, non-binary and gender fluid people) produce more than 1,000 new sperm every few seconds.

Progress in the field has been hindered by the fact that it's extremely difficult to distinguish SSCs from other cells in the testes. It was a major step forward when several laboratories, including the Wilkinson team,recently useda technique called single-cell RNA sequencing to define the likely molecular characteristics specific to human SSCs.

In their latest effort, the Wilkinson team used its single-cell RNA sequencing information to purify what it thought might be human SSCs. Using a method called germ-cell transplantation, it showed that the cells it purified were indeed highly enriched in human SSCs. The team then gathered the profile of genes expressed in these human SSCs to make guesses as to the conditions that might best support their growth in the lab. Using more than 30 human testis biopsies, the researchers determined just the right conditions needed to culture immature germ cells with the characteristics of SSCs.

The key ingredient was an inhibitor of the AKT pathway, a cellular system that controls cell division and survival. The Wilkinson team determined that AKT inhibition maintains human SSCs by inhibiting development of later-stage sperm precursors. Several AKT inhibitors are currently used to treat cancer.

With that approach, the researchers were able to favor the culture of human cells with the molecular characteristics of SSCs for two-to-four weeks.

"Next, our main goal is to learn how to maintain and expand human SSCs longer so they might be clinically useful," Wilkinson said.

Human sperm stem cells grown in lab, an early step toward infertility treatment - Jill Lopez

Global Stem Cell and Primary Cell Culture Medium Industry 2020 Market Research With Size, Growth, Manufacturers, Segments And 2026 Forecasts Research…

IndustryGrowthInsights has published a detailed report on the Stem Cell and Primary Cell Culture Medium market. This market research report was prepared after considering the COVID-19 impacts and monitoring the market for a minimum of five years. The report provides you with growing market opportunities, revenue drivers, challenges, pricing trends & factors, and future market assessments. Our research team has implemented a robust research methodology that includes SWOT analysis, Porters 5 Force analysis, and real-time analysis. Furthermore, they have conducted interviews with the industry experts to offer a report that helps the clients to formulate strategies accordingly.

The Global Stem Cell and Primary Cell Culture Medium Market has outlined the supply and demand scenario in the industry and provided a detailed analysis of the product developments, technology advancements, and competitive analysis in the market. It offers an in-depth analysis and all the information required by the new entrants and emerging players to stay ahead in the competition. This report includes information on the latest government policies, norms, and regulations that have and can affect the dynamics of the market.

The historical and forecast information provided in the report span between 2018 and 2026. The report provides detailed volume analysis and region-wise market size analysis of the market.

Get a sample copy of the report including the analysis of COVID-19 impact:

IGI has laid out a dedicated section for the prominent companies in the market which provides information on their revenue drivers, product innovation, and challenges they are facing during in the industry. This company profiling section includes industry players mergers, acquisitions, and collaborations which have helped them to leverage or impacted their market position. Besides this, the report is fragmented on the basis of the products, applications, and region-based analysis which imparts a holistic view and scope of the market.

The market research report also offers information on potential investment opportunities, strategic growth market analysis, and probable threats that will adhere to the client to systematically and creatively plan out the business models and strategies. The critical data analysis in the Stem Cell and Primary Cell Culture Medium market report is laid out in an upright way. This means that the information is represented in form of infographics, statistics, and uncomplicated graphs to make it an effortless and time-saving task for the client.

Complete Purchase of Latest Version Global Stem Cell and Primary Cell Culture Medium Market Study with COVID-19 Impact Analysis:

Market Segmentation

The Stem Cell and Primary Cell Culture Medium market report is fragmented into product types, applications, and regional analysis. In this report, the product flow, distribution, and possible future innovations are bestowed in a detailed manner. It also provides accurate calculations for product sales in terms of volume and value.

The applications of the products are discussed in a coherent way which includes potential future applications.

The Stem Cell and Primary Cell Culture Medium market is classified into:

The Study is segmented by following Product Type:

Liquid Media Powder Media

Major applications/end-users industry are as follows:

Biopharmaceutical Manufacturing Tissue Engineering & Regenerative Medicine Gene Therapy Other

Geographical Analysis:

Major Companies in the Market:

Merck STEMCELL Technologies Irvinesci Cell Applications, Inc Biological Industries Miltenyi Biotec Swiss Medica Clinic Promocell Creative Biolabs Lifeline Cell Technology ScienCell Research Laboratories Osiris Therapeutics NuVasive Chiesi Pharmaceuticals JCR Pharmaceutical Pharmicell Medi-post Anterogen Molmed Takeda (TiGenix)

We also offers customization of the report. This means that the report can be tailored considering a particular product, application, and region, suiting the clients needs. Moreover, additional company profiles can be added if asked.

Request a discount on the report:

The global Stem Cell and Primary Cell Culture Medium market report has gone through primary and secondary market research to provide a complete overview of the market. Our dedicated research analyst team has gathered information from the company and official government websites while interviewed directors and VPs of the company to prepare the market report effectively. This enables the client to get a thorough understanding of the market which is supported by the most accurate facts and figures.

The report provides entry-level and top-winning strategies which can assist the industry players to gain high ROI. Moreover, you can call our research analysts (24/7) to clear the clients doubts even after the report is bought by you. We also provides quarterly/yearly report updates to the clients inbox which helps them to stay relevant to the innovative trends in the market.

Get on the call with our research analyst if you have any particular doubts before buying the report @

About Us:

Our reports are more than just research reports to us. They are tools that enable us to maintain long-term relationships with our clients whom we honor and cherish. Our clients business growth is integral for not only them but also us. This is what differentiates us from other market research companies.

At IGI, we provide our expertise and guideline for success. Our team of efficient and experienced researchers and consultants provide progressive market intelligence reports that are accurate, authentic, and in-depth. This empowers the clients to make well-informed decisions.

Moreover, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries including chemicals and materials, energy, automobile, healthcare, consumer goods, and technology. Our deep understanding of many business environments across industries such as those mentioned above allows us to deliver tailor-made reports.

Contact Us:

Alex Mathews Head of Business Development Phone No.: +1 909 545 6473 Email [emailprotected] Website Address 500 East E Street, Ontario, CA 91764, United States.

Read the original here:
Global Stem Cell and Primary Cell Culture Medium Industry 2020 Market Research With Size, Growth, Manufacturers, Segments And 2026 Forecasts Research...